-
Mashup Score: 0Adjuvant Atezolizumab/Bevacizumab Shows Recurrence-Free Survival Benefit Over Active Surveillance in HCC - 1 year(s) ago
Combined adjuvant treatment with atezolizumab and bevacizumab was determined to deliver a statistically significant recurrence-free survival benefit to patients with resected hepatocellular carcinoma.
Source: Oncology Nursing NewsCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 0
Moderna and Merck & Co. have presented positive mid-stage data at the American Association for Cancer Research (AACR) Annual Meeting 2023 for the combination of their personalized cancer vaccine (PCV) candidate and Merck’s blockbuster cancer immunotherapy Keytruda® (pembrolizumab).
Categories: Future of Medicine, Latest HeadlinesTweet
-
Mashup Score: 0
Findings presented at the AACR meeting show that adding an mRNA vaccine to leading immunotherapy pembrolizumab dramatically reduced melanoma recurrence.
Categories: Future of Medicine, Latest HeadlinesTweet
-
Mashup Score: 0
Results show GRAIL’s methylation-based test has strong analytical sensitivity, specificity, precision, and reliability in many solid tumors.
Categories: Future of Medicine, Latest HeadlinesTweet
-
Mashup Score: 0Pembrolizumab in Addition to Cisplatin and Gemcitabine Boosts Overall Survival in Advanced Biliary Tract Cancer - 1 year(s) ago
Patients who received pembrolizumab plus cisplatin and gemcitabine achieved a median overall survival of 12.7 months, compared with 10.9 months with cisplatin and gemcitabine alone.
Source: Oncology Nursing NewsCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 2Drug Combo Improves Recurrence-Free Survival After HCC Resection - 1 year(s) ago
The atezolizumab-bevacizumab combination is the first to show efficacy in the adjuvant setting after HCC resection for patients at high risk for recurrence, but the overall survival benefit is unclear.
Source: MedscapeCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 0Pembrolizumab in Addition to Cisplatin and Gemcitabine Boosts Overall Survival in Advanced Biliary Tract Cancer - 1 year(s) ago
Patients who received pembrolizumab plus cisplatin and gemcitabine achieved a median overall survival of 12.7 months, compared with 10.9 months with cisplatin and gemcitabine alone.
Source: Oncology Nursing NewsCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 0
Moderna and Merck & Co. have presented positive mid-stage data at the American Association for Cancer Research (AACR) Annual Meeting 2023 for the combination of their personalized cancer vaccine (PCV) candidate and Merck’s blockbuster cancer immunotherapy Keytruda® (pembrolizumab).
Categories: Future of Medicine, Latest HeadlinesTweet
-
Mashup Score: 1Adjuvant Atezolizumab/Bevacizumab Shows Recurrence-Free Survival Benefit Over Active Surveillance in HCC - 1 year(s) ago
Combined adjuvant treatment with atezolizumab and bevacizumab was determined to deliver a statistically significant recurrence-free survival benefit to patients with resected hepatocellular carcinoma.
Source: Oncology Nursing NewsCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 8
Findings presented at the AACR meeting show that adding an mRNA vaccine to leading immunotherapy pembrolizumab dramatically reduced melanoma recurrence.
Categories: Future of Medicine, Latest HeadlinesTweet
Combined adjuvant treatment with atezolizumab and bevacizumab was determined to deliver a statistically significant recurrence-free survival benefit to patients with resected hepatocellular carcinoma. #AACR #HCC #hpbcsm #oncology #nursing #AACR23 https://t.co/3vzYSPi7e3 https://t.co/gClGEovwxN